EMA grants Marketing Authorization for Chenodeoxycholic Acid Leadiant

By | Uncategorized | No Comments

Leadiant GmbH, a fully owned subsidiary of Leadiant Biosciences Limited, has been granted Marketing Authorization by the European Commission for Chenodeoxycholic Acid Leadiant in the treatment of inborn errors of primary bile acid synthesis due to sterol-27-hydroxylase deficiency, presenting as cerebrotendinous xanthomatosis (CTX) in infants, children and adolescents aged 1 month to 18 years, and adults.

Read More